Phaseline

Companies › Daewoong Pharmaceutical

Daewoong Pharmaceutical: clinical trials, targets and expected readouts

7 active drug programs in 12 registered trials: 11 Phase 1, 1 Phase 2; Other, Metabolic and endocrine, Respiratory, Immunology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
DWN12088–Phase 2Idiopathic Pulmonary FibrosisJan 2027
DWRX5003
GLP-1 receptor agonist delivered via microneedle patch
GLP1RPhase 1Obesity & OverweightNov 2026
DWP212525–Phase 1Autoimmune DiseasesDec 2026
Olaparib (DWZ2501)
PARP 1, 2 and 3 inhibitor
PARP1, PARP3, PARP2Phase 1CancerMar 2027
DWC202313–Phase 1Healthy Volunteers–
DWJ1511–Phase 1Healthy Subjects–
DWJ1622–Phase 1Healthy Volunteers–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07144176DWJ1511Phase 1Healthy SubjectsOtherSep 2025
NCT07260851DWJ1622Phase 1Healthy VolunteersOtherJan 2026
NCT07267221DWJ1622Phase 1Healthy VolunteersOtherJan 2026
NCT07260851DWC202313Phase 1Healthy VolunteersOtherJan 2026
NCT07260851DWC202313Phase 1Healthy VolunteersOtherJan 2026
NCT07267221DWC202313Phase 1Healthy VolunteersOtherJan 2026
NCT07267221DWC202313Phase 1Healthy VolunteersOtherJan 2026
NCT07539415DWRX5003Phase 1Obesity & OverweightMetabolic and endocrineNov 2026
NCT06736587DWP212525Phase 1Autoimmune DiseasesImmunologyDec 2026
NCT05389215DWN12088Phase 2Idiopathic Pulmonary FibrosisRespiratoryJan 2027
NCT07371104Olaparib (DWZ2501)Phase 1CancerOncologyMar 2027
NCT07371104Olaparib (DWZ2501)Phase 1CancerOncologyMar 2027

Targets

GLP1R (1) PARP1 (1) PARP3 (1) PARP2 (1)

Companies with the same targets

AstraZeneca Eli Lilly Novo Nordisk Merck & Co. (MSD) Roche Pfizer Hangzhou Sciwind Biosciences pharmaand Boryung Pharmaceutical Hangzhou Zhongmei Huadong Pharmaceutical

Companies built like this

Yuhan Beijing QL Biopharmaceutical Basilea Pharmaceutica Shanghai Argo Biopharmaceutical Shanghai Minwei Biotechnology

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.